Daily Respiratory Research Analysis
Analyzed 185 papers and selected 3 impactful papers.
Summary
Three impactful studies span critical care, interventional support, and respiratory prevention. A 30,516-patient analysis shows predicted body weight misestimates female lung size, increasing injurious driving pressures and mortality mediation. An international ARDS cohort details outcomes of ECMO without intubation, while a bioadhesive inhalable barrier demonstrates lower-airway protection and particulate clearance in animal models.
Research Themes
- Precision ventilation and sex-specific lung mechanics in critical care
- Non-intubated ECMO strategies and determinants of failure in ARDS
- Inhalable biomaterials to prevent particulate-induced lung injury
Selected Articles
1. The predicted body weight equation overestimates lung sizes of female, critically ill patients: an analysis of randomized, controlled trials and real-world clinical data.
Across 30,516 ventilated patients, PBW-standardized tidal volumes exposed women to a 4.2% higher absolute risk of high driving pressure (aOR 1.26), mediating 8.4% of excess 28-day mortality. At the same PBW, women had substantially smaller anatomical and aerated lung volumes than men, indicating systematic lung size overestimation by PBW in females.
Impact: This large, multi-dataset analysis identifies a sex-specific bias in a cornerstone ventilation metric, linking PBW-based dosing to injurious pressures and mortality mediation in women. It motivates practice shifts toward driving pressure-guided, sex-aware ventilation strategies.
Clinical Implications: Consider titrating tidal volume to lung stress (driving pressure) rather than PBW alone, especially in females; reassess PBW equations or apply sex-specific adjustments. Monitor driving pressure targets and consider bedside measures of aerated lung (e.g., EIT/CT surrogates) when feasible.
Key Findings
- Women had a 4.2% (95% CI 3.2–5.3) higher absolute risk of driving pressure ≥15 cmH2O at similar PBW-standardized tidal volumes.
- High driving pressure mediated 8.4% of excess 28-day mortality in females.
- At the same PBW, female patients had lower anatomical (-343 ml) and aerated (-188 ml) lung volumes than males.
Methodological Strengths
- Very large, multicenter dataset integrating 10 RCTs and two real-world cohorts
- Robust multivariable and mediation analyses linking physiology to mortality
Limitations
- Observational secondary analyses preclude causal inference despite robustness
- PBW misestimation mechanisms (anthropometry vs lung size) not directly measured at bedside
Future Directions: Prospective trials of driving pressure-guided ventilation stratified by sex; validation of sex-adjusted PBW or imaging-informed dosing; development of bedside surrogates for aerated lung volume to individualize Vt.
PURPOSE: Low tidal volume (Vt) ventilation is the standard of care among critically ill patients. Guidelines recommend scaling Vt to the predicted body weight (PBW) to avoid ventilator-induced lung injury (VILI). Concerns exist that the PBW overestimates lung volumes of critically ill females. We investigated whether this applies to clinically relevant measures of lung volume, whether PBW-guided mechanical ventilation yields comparable risk of lung stress among male and female patients, and whether this affects mortality. METHODS: Mechanically ventilated, critically ill patients from ten randomized trials and two real-world retrospective clinical datasets were analyzed. Risk of high driving pressures (≥ 15 cmH RESULTS: Among 30,516 patients (39.4% female), ventilation with comparable tidal volumes standardized to PBW (ml/kg PBW) was associated with 4.2% (95% CI 3.2-5.3; aOR 1.26, 95% CI 1.19-1.33; p < 0.001) higher absolute risk of high driving pressures among females, mediating 8.4% of excess 28-day mortality (p < 0.001). At the same PBW, female patients had lower anatomical and aerated lung volumes (- 343 ml, 95% CI - 449 to - 237, p < 0.001; and - 188, 95% CI - 282 to - 94, p < 0.001, respectively) than males. CONCLUSIONS: The widely used PBW equation overestimates lung volumes in female critically ill patients, resulting in excess risk of injurious driving pressures among females, mediating higher mortality. Personalized mechanical ventilation by using driving pressure-guided strategies might mitigate these disparities.
2. Extracorporeal membrane oxygenation without invasive mechanical ventilation for acute respiratory distress syndrome: an international cohort study.
In 307 ARDS patients supported with ECMO without concurrent IMV, 90-day mortality was 30.1% for primary awake ECMO and 14.9% for extubated ECMO. Strategy failure occurred early and was the dominant predictor of death (HR ~6–8), with distinct leading causes (delirium and worsening gas exchange vs secretion management).
Impact: Defines real-world outcomes and failure determinants for non-intubated ECMO strategies in ARDS, informing patient selection, monitoring, and early rescue thresholds.
Clinical Implications: Select candidates thoughtfully; anticipate and mitigate early failure risks: aggressive secretion management for extubated ECMO and proactive delirium prevention for awake ECMO. Use predefined thresholds to revert to IMV when strategy failure emerges.
Key Findings
- 90-day mortality: 30.1% (primary awake ECMO) vs 14.9% (extubated ECMO).
- Strategy failure rates: 40.7% and 24.2%, mostly within 10 days of ECMO start.
- Strategy failure independently associated with mortality (HR 5.95–7.67 across groups).
Methodological Strengths
- Multinational, multicenter cohort reflecting diverse practices
- Prespecified primary outcome with multivariable modeling of failure and mortality
Limitations
- Retrospective design subject to selection bias and unmeasured confounding
- No randomized comparison to conventional intubated ECMO or standard IMV
Future Directions: Prospective registries and pragmatic trials to refine indications, sedation/airway protocols, and failure rescue algorithms; patient-reported outcomes and long-term functional recovery.
RATIONALE: In acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO) without invasive mechanical ventilation (IMV) is particularly challenging. OBJECTIVES: To study ARDS patients treated with ECMO to avoid IMV-'primary awake ECMO'-or with extubation during ECMO support - 'extubated ECMO'. METHODS: International retrospective cohort of adult ARDS patients treated with ECMO without IMV at 14 centers in 8 countries (2015-2024). The primary outcome was mortality 90 days after ECMO initiation. MEASUREMENTS AND MAIN RESULTS: Among 307 adult patients with ARDS, 113 received 'primary awake ECMO' and 194 were extubated on ECMO. Ninety-day mortality was 30.1% in the 'primary awake ECMO' group and 14.9% in the 'extubated ECMO'. Strategy failure occurred in 46 patients (40.7%) and 47 patients (24.2%), respectively, most frequently within the first 10 days. In multivariate analysis, strategy failure was associated with 90-day mortality (hazard ratio 7.67 (3.44-17.11); P < .001 in 'extubated ECMO'; hazard ratio 5.95 (2.63-13.46); P < .001 in 'primary awake ECMO'), while higher age and longer time from ICU admission to ECMO cannulation were associated with 90-day mortality in 'extubated ECMO' and 'primary awake ECMO', respectively. The leading cause of strategy failure was worsening of respiratory failure, followed by agitation/delirium in 'primary awake ECMO' and inability to clear secretions in 'extubated ECMO'. CONCLUSIONS: Patients selected for 'primary awake ECMO' and 'extubated ECMO' presented different baseline characteristics, strategy failure, and 90-day mortality rates. However, strategy failure was consistently associated with 90-day mortality in both groups.
3. Inhalable bioadhesive barrier for lung protection and clearance of fine particulate matter.
An inhalable bioadhesive hydrogel is engineered to deposit throughout the lower airways, adhere to mucus, and scavenge fine particulates, maintaining protection for up to 8 hours and enabling clearance within 48 hours. It outperformed nasal sprays in a murine silicosis model, and porcine studies showed uniform bronchial coverage, supporting translational potential.
Impact: Introduces a first-in-class inhalable barrier that targets the lower airways to prevent PM-induced disease, bridging a translational gap with supportive large-animal data.
Clinical Implications: If proven safe in humans, IBB could offer occupational and environmental protection (e.g., wildfire smoke, mining, urban pollution) beyond masks and sprays, particularly for vulnerable individuals with chronic respiratory disease.
Key Findings
- Optimized aerodynamic IBB deposits throughout bronchi/bronchioles and provides up to 8-hour protection.
- IBB captures and encapsulates PM, enabling airway clearance within 48 hours and reducing long-term retention.
- Outperformed commercial nasal sprays in a murine silicosis model; porcine studies showed uniform airway coverage.
Methodological Strengths
- Rational aerodynamic design with in vivo validation in both murine disease and large-animal (porcine) models
- Demonstrated functional endpoints: deposition, protection duration, and accelerated particulate clearance
Limitations
- No human safety/efficacy data; long-term repeat dosing safety unknown
- Potential variability of deposition across disease phenotypes and airway conditions not fully characterized
Future Directions: Phase I safety studies, human deposition imaging, and controlled trials in high-exposure settings; optimization of dosing schedules and evaluation in chronic lung disease cohorts.
Fine particulate matter (PM) can bypass nasal filtration and accumulate in the lower respiratory tract, where prolonged deposition may cause chronic inflammation, pulmonary fibrosis, and other respiratory diseases. Although commercial nasal sprays offer protection in the upper airways, they are inadequate for safeguarding the lower respiratory tract and lung. In this study, we introduce an inhalable bioadhesive barrier (IBB) specifically engineered to deposit in the lower airways, where it forms an adhesive hydrogel barrier upon contact with airway mucus and actively scavenges inhaled fine PM. With optimized aerodynamic properties, IBB can efficiently deposit throughout the bronchi and bronchioles, providing protection for up to 8 h. The IBB captures and encapsulates inhaled PM, enabling its clearance from the airways within 48 h, thus preventing long-term retention. Compared to commercial nasal sprays, intranasal inhalation of IBB markedly improved protection against chronic silica exposure in a murine silicosis model. Large animal studies further demonstrated uniform and extensive airway coverage by IBB in porcine models, suggesting strong translational potential for human respiratory protection. This approach provides a safe, efficient, and cost-effective strategy for preventing respiratory diseases induced by chronic exposure to respirable fine particulates.